# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

---

**Tucson, 1980 — The melanocortin switchboard**

# Melanotans chased a desert tan: three prescription medicines, two online analogs.

In 1980, chemists built an [enzyme-resistant α-MSH analog](https://pubmed.ncbi.nlm.nih.gov/6777774/). Natural melanocortins share a [conserved `His-Phe-Arg-Trp` core](https://pubmed.ncbi.nlm.nih.gov/26916163/), yet [each receptor requires its own motif—17 ACTH residues at MC2R, `Phe-Arg-Trp` at MC4R, four at MC1R/MC3R/MC5R](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). After [1989 Arizona cyclic synthesis](https://pubmed.ncbi.nlm.nih.gov/2555512/), a [1996 clinical pilot observed erections and nausea alongside tanning](https://pubmed.ncbi.nlm.nih.gov/8637402/), framing today's split between Scenesse, Vyleesi, Imcivree, and online Melanotan I and II.

- [Trace the Five Switches](#interactive-receptor-ledger-why-one-four-amino-acid-sequence-crosses-five-organs)
- [Read six-jurisdiction regulator texts](/regulatory-warnings)

**Field Record 01 · Sonoran UV:** Natural suntanning depends on [UV-driven p53 induction of POMC and α-MSH in skin](https://pubmed.ncbi.nlm.nih.gov/17350573/); synthetic analogs like afamelanotide [increase eumelanin independently of sunlight](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf).

## MC1R–MC5R Receptor Compass

Legend: Prescription | Online analogs

| Receptor | Biological Domain | Endogenous Physiology | Prescription | Online Analogs |
|---|---|---|---|---|
| **MC1R** | Skin & hair pigment | — | [Scenesse](/afamelanotide-scenesse) | [MT-I / MT-II](/melanotan-online-market) |
| **MC2R** | Adrenal cortisol | Endogenous ACTH only | — | — |
| **MC3R** | Energy efficiency | — | — | [MT-II](/case-reports-and-safety) |
| **MC4R** | Appetite & arousal | — | [Imcivree](/setmelanotide-imcivree), [Vyleesi](/bremelanotide-vyleesi) | [MT-II](/case-reports-and-safety) |
| **MC5R** | Exocrine glands | — | — | [MT-II](/case-reports-and-safety) |

Conserved ligand core · [Compare EC50 at human receptors below](#interactive-receptor-ledger-why-one-four-amino-acid-sequence-crosses-five-organs)

---

## The Split Trail: One molecular family, divided by receptor fences and regulatory testing

Pharmaceutical programs spent decades narrowing which melanocortin switches a peptide hits, how it is formulated, and which patients qualify. Online tanning markets operate outside clinical trials and manufacturing verification.

### Prescription Medicines · Dry-Sky Slate Ledger: Three prescription melanocortin medicines

#### Afamelanotide (Scenesse)
Linear 13-amino-acid peptide · Bioresorbable implant · Predominantly MC1R

The [1980 linear 13-amino-acid peptide](https://pubmed.ncbi.nlm.nih.gov/6777774/), formulated as a [controlled-release subcutaneous rod](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf). EMA's [EPAR (last updated October 7, 2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse) states: "The European Commission granted a marketing authorisation valid throughout the European Union for Scenesse on 22 December 2014." FDA's [orphan-drug record](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208) lists "Marketing Approval Date: 10/08/2019," and FDA's [October 2019 prescribing label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf) states: "SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)."

[Read the Scenesse clinical dossier](/afamelanotide-scenesse)

#### Bremelanotide (Vyleesi)
Cyclic 7-amino-acid peptide · Free acid (-OH) · Nonselective MCR agonist

A [cyclic heptapeptide with a free acid at the carboxyl terminus (`-OH`)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf)—the [deaminated derivative of Melanotan II](https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/), which ends in an [amide group (`-NH2`)](https://pubmed.ncbi.nlm.nih.gov/8637402/). FDA's [June 21, 2019 approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf) and [June 2019 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) state: "VYLEESI is a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance." The label adds: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men." "VYLEESI is not indicated to enhance sexual performance." "VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease."

[Read the Vyleesi clinical dossier](/bremelanotide-vyleesi)

#### Setmelanotide (Imcivree)
Cyclic 8-amino-acid disulfide peptide · MC4R agonist

A cyclic 8-amino-acid peptide with [20-fold less activity at MC3R and MC1R than at MC4R](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf). FDA's [prescribing information (Initial U.S. Approval: 2020; Revised: 03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) states: "IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)." EMA's [EPAR (last updated May 27, 2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree) states: "Imcivree received a marketing authorisation valid throughout the EU on 16 July 2021."

[Read the Imcivree clinical dossier](/setmelanotide-imcivree)

### Online Tanning Analogs · Desert Ochre Ledger: Online Melanotan I & II: lab assays and hospital cases

#### Underfilled containers and chemical impurities
LC-UV-MS/MS assays of online vials and seized peptide screening

In an LC-UV-MS/MS analytical chemistry study ([Breindahl et al., 2015](https://pubmed.ncbi.nlm.nih.gov/24771717/)) of Melanotan II vials purchased from three online shops, each shop claimed its vials contained 10 mg, yet [measured total peptide content per vial ranged from 4.32 to 8.84 mg](https://pubmed.ncbi.nlm.nih.gov/24771717/), with [4.1% to 5.9% unknown impurities in vials from two shops](https://pubmed.ncbi.nlm.nih.gov/24771717/). Separately, a [2018 Belgian review of falsified biotechnology drugs](https://pubmed.ncbi.nlm.nih.gov/30165334/) listed melanotan II among falsified image-enhancing polypeptides, while a [companion Belgian analytical screen of ten frequently encountered falsified peptide drugs from three suspected illegal internet pharmacies](https://pubmed.ncbi.nlm.nih.gov/30029448/) found 5% to 75% purity in cysteine-containing peptides, lead in one sample, and inorganic arsenic up to ten times the ICH parenteral toxicity limit.

[Inspect the online market lab record](/melanotan-online-market)

#### Acute organ toxicity in emergency case reports
68-study systematic review (2026) and ICU / surgical case reports

A 2026 systematic review of [68 studies across several tanning agents reported rhabdomyolysis, renal infarction, and priapism in its discussion of unregulated melanotan use](https://pubmed.ncbi.nlm.nih.gov/41890775/). Published hospital case reports include a 39-year-old man admitted for a [3-day ICU stay with apparent sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction](https://pubmed.ncbi.nlm.nih.gov/23121206/) after exposure to mass-spectrometry-confirmed Melanotan II (Nelson et al., 2012), and a 55-year-old man who underwent [penoscrotal decompression after a 30-hour ischemic priapism](https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/) (Mallory et al., 2021).

[Review the safety and causality audit](/case-reports-and-safety)

#### Darkening moles and what melanoma reports can prove
Dermatologic case series, confounders, and causality limits

Clinical reviews tie unregulated melanotan use in case reports to [melanocytic changes in existing moles and newly emerging dysplastic nevi](https://pubmed.ncbi.nlm.nih.gov/28266027/), which [can complicate clinical presentation of pigmented lesions](https://pubmed.ncbi.nlm.nih.gov/20545686/). At least [five melanoma cases have been reported during or after Melanotan II use](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/), all involving other risk factors such as fair skin, excess sun or tanning-bed use, or family history. As [Vadner & Smith (2026) note](https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/), causality cannot be established from a single observational case. On January 24, 2025, [Australia's TGA](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan) stated: "Use of melanotan to increase skin pigmentation artificially will not protect against UV exposure the way a suitable sunscreen will."

[Read the melanoma causality audit](/case-reports-and-safety)

### Primary Regulatory Record: Verbatim Dated Texts (2024–2026)

[Compare all six jurisdictions verbatim](/regulatory-warnings)

- **U.S. FDA (content current as of April 22, 2026):** On its [bulk drug substances safety page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), FDA notes: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators." Under Melanotan II, FDA states: "Melanotan II: Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism."
- **U.S. HHS Draft Policy (published October 30, 2026, 91 FR 68526):** In the [Federal Register notice](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances), HHS states: "HHS is announcing the availability of a draft 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.'" "The draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances does not establish any rights for any person and is not binding on HHS or the public." The [draft policy text](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) states: "Therefore, to expand and improve patient access while FDA reviews these substances, in the circumstances below, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A." Appendix A lists six substances—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—and does not include Melanotan II.
- **Australia TGA (January 24, 2025):** In its [public safety warning](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan), TGA states: "Melanotan is not approved for sale or use as a tanning agent in Australia. These tanning agents haven’t been assessed for their quality or safety." "It is illegal to supply tanning products containing melanotan without a doctor’s prescription. These restrictions apply regardless of whether it is a spray, a tablet, an injection, a cream or in any other form."
- **New Zealand Medsafe (May 21, 2026):** Listing melanotan II among advertised online peptides, [Medsafe's consumer advisory](https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp) states: "Medsafe has NOT assessed these products for quality, safety or efficacy. They are unapproved products." "Many sellers label these products as 'for research purposes only'. This wording has no legal effect and does not permit sale, supply, or use in people."
- **UK MHRA (April 17, 2024):** In [FOI 24/274](https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf), MHRA states: "Products containing Melanotan II are classified as medicines if they are injectable or pens. If a product contains Melanotan II and is in the form of a nasal spray, it will be determined as a medicine only if sold with claims to treat or prevent disease." "It is important to note that the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations."

---

## Interactive Receptor Ledger: Why one four-amino-acid sequence crosses five organs

All five human melanocortin receptors are G protein-coupled receptors—cell-surface switches that relay chemical signals inside a cell—sharing [38% to 60% sequence identity](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/). Every natural agonist cleaved from the precursor protein pro-opiomelanocortin (POMC) carries the conserved [four-amino-acid sequence `His-Phe-Arg-Trp`](https://pubmed.ncbi.nlm.nih.gov/26916163/). Below are the five switches paired with in vitro EC50 potency figures at human melanocortin receptors (the concentration producing half-maximal activation in nanomolar; lower numbers indicate higher potency) compiled by [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/).

**Filter melanocortin receptors:** All Five · MC1R · Pigment · MC2R · Adrenal · MC3R · Energy · MC4R · Appetite & Arousal · MC5R · Exocrine

### MC1R — Skin & hair melanocytes
Shifts pigment synthesis toward photoprotective black eumelanin rather than [red pheomelanin, which can generate free radicals under UV](https://pubmed.ncbi.nlm.nih.gov/7581459/), and [promotes UV-induced DNA nucleotide excision repair](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/). Target of prescription afamelanotide (Scenesse), and also why MC4R agonist setmelanotide still produced [skin hyperpigmentation in 67% of trial patients aged 6 and older](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf) on FDA's December 2024 label.

- EC50 at human receptors (Yuan & Tao, 2022): Native α-MSH 1.01 nM; Afamelanotide (NDP-MSH) 0.462 nM; Bremelanotide* 0.095 nM; Setmelanotide 5.8 nM; Melanotan II 0.2 nM.

### MC2R — Adrenal cortex
Regulates adrenal cortical function and obeys strict selectivity: [adrenocorticotropic hormone (ACTH) is the only endogenous ligand for MC2R](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/), requiring [the first 17 amino acids of ACTH](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). As [Yang (2011) notes](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/), substituting phenylalanine-7 with D-phenylalanine (`D-Phe7`) in ACTH decreases binding affinity and potency at MC2R, whereas substituting `Phe7` with `D-Phe` in MSH increases affinity and potency at MC1R, MC3R, MC4R, and MC5R.

- Selectivity boundary (Yang, 2011): Endogenous agonist ACTH only; α-, β-, γ-MSH no binding; D-Phe7 in ACTH lower MC2R affinity.

### MC3R — Hypothalamus & limbic brain
One of two central neural melanocortin receptors; mouse knockout studies showed [MC3R regulates feed efficiency](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) in a role distinct from MC4R. In receptor assays compiled by [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/), Melanotan II activates human MC3R at subnanomolar potency (0.51 nM).

- EC50 at human receptors (Yuan & Tao, 2022): Native α-MSH 1.04 nM; Afamelanotide (NDP-MSH) 0.109 nM; Bremelanotide* 2.4 nM; Setmelanotide 5.3 nM; Melanotan II 0.51 nM.

### MC4R — Hypothalamus & autonomic circuits
Regulates [food intake and energy balance in mouse knockout studies](https://pubmed.ncbi.nlm.nih.gov/9019399/) alongside [central pathways involved in sexual response](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/). Targeted in rare obesity by prescription setmelanotide (Imcivree) and central to prescription bremelanotide (Vyleesi), whose [June 2019 FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf) states that binding to MC1R and MC4R is most relevant at therapeutic levels and "The mechanism by which VYLEESI improves HSDD in women is unknown." Melanotan II activates human MC4R at [0.05 nM in human-receptor assays](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) and was associated with [spontaneous erections, nausea, and yawning in a 1996 pilot human study](https://pubmed.ncbi.nlm.nih.gov/8637402/).

- EC50 at human receptors (Yuan & Tao, 2022): Native α-MSH 4.7 nM; Afamelanotide (NDP-MSH) 0.075 nM; Bremelanotide* 0.25 nM; Setmelanotide 0.27 nM; Melanotan II 0.05 nM.

### MC5R — Exocrine & sebaceous glands
Expressed across human peripheral tissues and [linked primarily to exocrine and sebaceous gland secretion in targeted-deletion studies](https://pmc.ncbi.nlm.nih.gov/articles/PMC3095696/). Setmelanotide shows weak human MC5R potency (1600 nM EC50), whereas [Melanotan II activates human MC5R at 5.33 nM](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/).

- EC50 at human receptors (Yuan & Tao, 2022): Native α-MSH 10.5 nM; Afamelanotide (NDP-MSH) 0.253 nM; Setmelanotide 1600 nM; Melanotan II 5.33 nM.

In vitro EC50 values at human melanocortin receptors are compiled from Table 3 of [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) (primary assay set from Kievit et al., 2013; *bremelanotide from Durek et al., 2018, where MC5R was not reported). In vitro receptor potency does not measure brain penetration or clinical tissue distribution; [read the full receptor biology ledger](/five-receptors).

---

## The Tucson Origin: How a sunless-tanning project collided with neurobiology

**Field Record 02 · Sonoran Ridge:** From 1980 synthesis in Tucson to 2026 Phase 3 hypothalamic obesity trials, four decades of peptide chemistry grew out of efforts to study how skin responds to intense desert ultraviolet light.

Native alpha-melanocyte-stimulating hormone darkens pigment cells, yet degrades rapidly in blood. In 1980, researchers reported `[Nle4, D-Phe7]-α-MSH`, a synthetic analog [resistant to serum enzymes and 26 times as potent as native hormone in mouse melanoma adenylate cyclase assays](https://pubmed.ncbi.nlm.nih.gov/6777774/). By 1991, a [University of Arizona randomized, double-blind trial in 28 healthy white men wearing high-potency sunscreen](https://pubmed.ncbi.nlm.nih.gov/1658407/) showed the peptide darkened human skin without ultraviolet light.

University of Arizona chemists later synthesized a [23-membered cyclic peptide later named Melanotan II, which had 90 times the potency of native α-MSH in the lizard skin assay](https://pubmed.ncbi.nlm.nih.gov/2555512/). In a [1996 University of Arizona pilot study of three normal male volunteers](https://pubmed.ncbi.nlm.nih.gov/8637402/), investigators observed increased skin pigmentation in two subjects alongside mild nausea, stretching and yawning, and intermittent 1- to 5-hour spontaneous erections. A [1998 double-blind crossover trial in 10 men with psychogenic erectile dysfunction](https://pubmed.ncbi.nlm.nih.gov/9679884/) subsequently recorded clinically apparent erections in 8 of 10 men (mean tip rigidity above 80% for 38.0 minutes versus 3.0 minutes on placebo, *p* = 0.0045).

[Read the full 1916–2026 origin dispatch](/tucson-origin)

### Four verified benchmark figures from primary literature

- **26×** — [Potency of `[Nle4, D-Phe7]-α-MSH` over native α-MSH](https://pubmed.ncbi.nlm.nih.gov/6777774/) in a 1980 mouse melanoma adenylate cyclase assay.
- **34 years** — [Span from 1980 synthesis to the December 22, 2014 EU marketing authorization](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) of [afamelanotide (Scenesse)](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse).
- **4.1%–5.9%** — [Unknown chemical impurities in Melanotan II vials from two of three online shops](https://pubmed.ncbi.nlm.nih.gov/24771717/) tested by LC-UV-MS/MS (Breindahl et al., 2015), with vial contents below labeled weight.
- **−16.5% vs +3.3%** — [52-week BMI change with setmelanotide vs placebo in 120 patients](https://pubmed.ncbi.nlm.nih.gov/42418774/) with acquired hypothalamic obesity (NEJM, July 9, 2026).

---

## Field Dispatches: Eight source-linked reports across discovery, medicine, and regulation

Every chapter links claims directly to opened journal papers, FDA and EMA prescribing records, and dated national regulator advisories—keeping animal assays, single case reports, and randomized human trials clearly labeled.

### Part I · Origin & Receptor Biology
1. **[01. The Tucson Switchboard Accident](/tucson-origin)** — From 1916 melanocortin discovery and 1980 serum-stable synthesis to the 1991 JAMA UV-free tanning trial, the 1996 and 1998 Melanotan II clinical studies, and how one lab bench forked into clinical medicines and online products. — [Read dispatch](/tucson-origin)
2. **[02. Five Receptors, One Four-Letter Key](/five-receptors)** — How UV activates p53 and POMC, why MC1R–MC5R overlap structurally, why MC2R requires ACTH's first 17 amino acids, EC50 potency at human receptors, and preclinical biased Gαq signaling. — [Read dispatch](/five-receptors)

### Part II · Prescription Medicines (Dry-Sky Slate)
3. **[03. Afamelanotide (Scenesse)](/afamelanotide-scenesse)** — How Melanotan I became a clinician-placed bioresorbable implant for adult erythropoietic protoporphyria, what US CUV039 and EU CUV029 measured in pain-free sunlight hours, and what skin surveillance tracks. — [Read dossier](/afamelanotide-scenesse)
4. **[04. Bremelanotide (Vyleesi)](/bremelanotide-vyleesi)** — One carboxyl group away from Melanotan II: RECONNECT Phase 3 desire and distress scores, the null secondary endpoint on satisfying sexual events, high nausea rates, blood-pressure limits, and daily-use hyperpigmentation. — [Read dossier](/bremelanotide-vyleesi)
5. **[05. Setmelanotide (Imcivree)](/setmelanotide-imcivree)** — MC4R agonism across POMC, PCSK1, and LEPR deficiency, Bardet-Biedl syndrome, and the 2026 U.S. FDA label revision and EU EPAR update covering acquired hypothalamic obesity—plus persistent MC1R and mood side effects. — [Read dossier](/setmelanotide-imcivree)

### Part III · Online Market, Case Reports & Regulators (Desert Ochre)
6. **[06. Online Melanotan I & II: Lab Assays](/melanotan-online-market)** — Forum and social-media surveillance, UK MHRA and Australia TGA product classifications, LC-UV-MS/MS underfilling and impurity studies, heavy-metal and microbial contamination in seized peptides, and research-label advisories. — [Read dispatch](/melanotan-online-market)
7. **[07. Case Reports, Moles & Causality](/case-reports-and-safety)** — Sympathomimetic toxidrome, rhabdomyolysis, refractory ischemic priapism, renal infarction, oral mucosal pigmentation, and an unvarnished audit of what melanoma case reports show—and cannot prove. — [Read dispatch](/case-reports-and-safety)
8. **[08. Regulatory Records From Six Jurisdictions](/regulatory-warnings)** — Side-by-side dated quotations from the U.S. FDA and HHS (including the April 22 and October 30, 2026 compounding records), EMA, UK MHRA, Australia TGA, New Zealand Medsafe, and Denmark's Medicines Agency. — [Read ledger](/regulatory-warnings)

Every figure, trial sample size, EC50 measurement, and regulatory quote across Melanotans traces back to 54 research papers, reviews, and official agency records. [Open 54-source ledger](/references) · [Editorial charter](/about) · [Contact notice](/contact)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [index.md](/index.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
